474 studies found for:    Open Studies | "Pancreatic Neoplasms"
Show Display Options
Rank Status Study
21 Recruiting Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
Conditions: Pancreatic Cancer;   Stage IV Pancreatic Cancer
Intervention: Drug: OMP-54F28, Nab-Paclitaxel and Gemcitabine
22 Recruiting A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
Conditions: Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: Vantictumab;   Drug: Nab-Paclitaxel;   Drug: Gemcitabine
23 Recruiting Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
Conditions: Colorectal Cancer;   Cancer of Pancreas;   Pancreatic Neoplasm;   Malignant Neoplasm of Large Intestine;   Malignant Tumor of Colon;   Colon Carcinoma;   Cancer of Colon;   Pancreatic Cancer
Interventions: Drug: FOLFOX6;   Biological: EGFRBi armed ATC Infusions
24 Recruiting Role of Cyberknife Stereotactic Radiation Therapy (SBRT) Followed by Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
Conditions: Pancreatic Cancer;   Unresectable Pancreatic Cancer
Intervention: Radiation: stereotactic body radiotherapy
25 Recruiting Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Conditions: Pancreatic Cancer;   Pancreatic Carcinoma Non-resectable;   Locally Advanced Malignant Neoplasm
Interventions: Drug: FOLFIRINOX;   Biological: Algenpantucel-L Immunotherapy;   Radiation: 5-FU Chemoradiation;   Drug: Gemcitabine;   Drug: Capecitabine;   Drug: Nab-Paclitaxel
26 Recruiting CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Intervention: Drug: 6,8-bis(benzylthio)octanoic acid
27 Recruiting Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer
Conditions: Locally Advanced Pancreatic Cancer;   Metastatic Pancreatic Cancer
Interventions: Drug: NC-6004;   Drug: Gemcitabine
28 Recruiting Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: oxaliplatin;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: 5-fluorouracil;   Drug: capecitabine;   Radiation: radiation;   Procedure: surgery;   Drug: gemcitabine hydrochloride
29 Recruiting Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: veliparib;   Drug: gemcitabine hydrochloride;   Drug: cisplatin;   Other: laboratory biomarker analysis
30 Recruiting Combination Chemotherapy, Gemcitabine Hydrochloride, and Radiation Therapy Before Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage IIA Pancreatic Cancer;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: irinotecan hydrochloride;   Drug: fluorouracil;   Radiation: intensity-modulated radiation therapy;   Drug: gemcitabine hydrochloride
31 Not yet recruiting APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Recurrent Pancreatic Cancer;   Recurrent Renal Cell Cancer;   Stage III Pancreatic Cancer;   Stage III Renal Cell Cancer;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: siRNA-transfected peripheral blood mononuclear cells APN401;   Other: laboratory biomarker analysis
32 Recruiting Computer Tools for Improving Early Diagnosis and Treatment in Healthy Volunteers or Patients With Pancreatic Cancer or Who Are At Risk For Pancreatic Cancer or Who Have a Noncancer Pancreatic Disorder
Condition: Pancreatic Cancer
Interventions: Other: medical chart review;   Other: questionnaire administration;   Other: study of socioeconomic and demographic variables;   Procedure: biopsy
33 Recruiting Ketogenic Diet With Concurrent Chemoradiation for Pancreatic Cancer
Condition: Pancreatic Neoplasms
Intervention: Dietary Supplement: Ketogenic diet
34 Recruiting Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients
Condition: Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection.
Intervention: Drug: L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine
35 Recruiting Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: metformin hydrochloride;   Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: fluorouracil;   Other: laboratory biomarker analysis
36 Recruiting Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer
Conditions: Duct Cell Adenocarcinoma of the Pancreas;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: fluorouracil;   Radiation: radiation therapy;   Other: laboratory biomarker analysis
37 Recruiting CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: 6,8-bis(benzylthio)octanoic acid;   Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: irinotecan hydrochloride;   Drug: fluorouracil;   Other: laboratory biomarker analysis
38 Recruiting Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer
Conditions: Pancreatic Carcinoma Non-resectable;   Stage IV Pancreatic Cancer
Interventions: Drug: Gemcitabine;   Drug: nab-Paclitaxel
39 Recruiting Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Stage IIB Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions: Drug: gemcitabine hydrochloride;   Radiation: hyperfractionated radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: radiosurgery;   Procedure: diffusion-weighted magnetic resonance imaging
40 Recruiting Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
Conditions: Adenocarcinoma of the Pancreas;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: dovitinib lactate;   Drug: gemcitabine hydrochloride;   Drug: capecitabine;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay;   Other: pharmacological study

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years